Latest from MD Anderson

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rarity of fusions in patients with colorectal cancer (CRC).

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses next steps for research with acalabrutinib in mantle cell lymphoma.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses progress made with immunotherapy agents in gastrointestinal (GI) cancer.

William G. Wierda, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses pivotal updates in the field of chronic lymphocytic leukemia that were presented at the 2018 ASH Annual Meeting.

Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the efficacy of axicabtagene ciloleucel in patients with large B-cell lymphoma.

John Mendelsohn, MD, a 2016 Giants of Cancer Care^® in Scientific Advances in recognition of his groundbreaking research that led to the development of cetuximab, died January 7 at his home in Houston, Texas at the age of 82.

John Mendelsohn, MD, president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer therapy, died January 7, 2019 at his home in Houston, Texas.